Impact of Emicizumab on Hemophilia A Management
Author Information
Author(s): Muacevic Alexander, Adler John R, Dutta Anupam, Dutta Taniya S, Borbouah Luish, Duseja Yash, Bora Juhi, Gogoi Papori
Primary Institution: Assam Medical College and Hospital
Hypothesis
This study aimed to evaluate the impact of emicizumab prophylaxis on bleeding rates, joint health, functional activity, and quality of life in patients with congenital Hemophilia A.
Conclusion
Emicizumab significantly reduces bleeding, enhances joint health, and improves the quality of life in patients with Hemophilia A.
Supporting Evidence
- At 24 weeks, the Hemophilia Joint Health Score improved significantly from 12.8 to 4.8.
- The Functional Independence Score in Hemophilia increased from 27.5 to 30.6.
- The annual bleeding rate decreased from 11.36 to 0.195.
- Quality of life scores improved significantly, with EQ-5D-5L index rising from 0.79 to 0.96.
- All 30 patients with target joints had resolved bleeds after treatment.
- Adherence to emicizumab was 100% among participants.
Takeaway
Emicizumab is a new treatment for a bleeding disorder that helps kids stop bleeding and feel better overall.
Methodology
A noninterventional, prospective observational study involving 40 patients with Hemophilia A, assessing various health metrics over 24 weeks.
Potential Biases
The observational nature of the study without a control group may introduce bias in attributing improvements solely to emicizumab therapy.
Limitations
The small sample size and single-center design may limit the generalizability of the results.
Participant Demographics
All participants were male, aged between three months and 16 years, with varying severity of Hemophilia A.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website